Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 675 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Active Chronic Graft Versus Host Disease Clear all
Completed Phase 4 Interventional Results available

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

NCT01277601
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01350128
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol, Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Panama City, Florida • Winter Park, Florida • Cherry Hill, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Behavioral Rx & Nutrition in Pediatric Chronic Disease

NCT01018121
View directory record Official record
Conditions
Pediatric Obesity
Interventions
LAUNCH, Pediatrician Counseling
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 5 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Not applicable Interventional Results available

Integrating Mind-Body Skills With Physical Activity to Improve Physical and Emotional Outcomes in Patients With Chronic Pain

NCT03412916
View directory record Official record
Conditions
Pain, Chronic Pain, Physical Activity
Interventions
GetActive, Get Active with Fitbit
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 10, 2026, 9:41 AM EDT
Completed No phase listed Observational

AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

NCT04057742
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
AlloSure ddcfDNA assay, AlloMap assay, Inflammatory Cytokines, Immune Cell Phenotypes
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Phase 2 Interventional

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT02064426
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Azusa, California • Long Beach, California • Lynwood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 10, 2026, 9:41 AM EDT
Completed No phase listed Observational

Association Between Activity and PROMIS Pediatric Measures in Children With Asthma

NCT03933540
View directory record Official record
Conditions
Pediatric Asthma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
8 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 10, 2026, 9:41 AM EDT
Active, not recruiting Not applicable Interventional

Motor Cortical Neuromodulation in Women With Interstitial Cystitis/Bladder Pain Syndrome

NCT04734847
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 10, 2026, 9:41 AM EDT
Withdrawn Phase 2 Interventional

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

NCT00323024
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
NX1011
Drug
Lead sponsor
NITROX, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2007 · Synced Oct 10, 2026, 9:41 AM EDT
Terminated No phase listed Observational

Acute Exacerbation of COPD and Physical Activity - Preliminary Study

NCT01871246
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT02680574
View directory record Official record
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
219
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Resistance Training and Diet in Patients With Chronic Renal Failure

NCT00018317
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
low protein diet, resistance training, combination of diet control and exercise
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 10, 2026, 9:41 AM EDT
Completed No phase listed Observational

Diet and Activity in Cerebral Palsy

NCT02175108
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Not listed
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
16 Years to 89 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

NCT02766608
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disorder
Interventions
BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg, BD MDI 320 μg, Symbicort® TBH 400/12 μg BID
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
83
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 10, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

NCT06049420
View directory record Official record
Conditions
Obesity, Hyperlipidemias, Polycystic Ovary Syndrome, Hypertension, Coronary Heart Disease, Heart Failure, Depression, Anxiety, Type II Diabetes, Metabolic Syndrome
Interventions
Lifestyle counseling and coaching
Behavioral
Lead sponsor
West Virginia School of Osteopathic Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lewisburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 10, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional

Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease

NCT05896579
View directory record Official record
Conditions
COPD, Pulmonary Hypertension, Right Ventricular Dysfunction, Exercise, Exercise Training
Interventions
Exercise
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 10, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional Results available

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

NCT01125917
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
84
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 10, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional

Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment

NCT06106191
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Mindfulness meditation, Perspectives on pain, Discussion
Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Upper Extremity Function Before and After Hippotherapy in Children With Autism Spectrum Disorder and/or Cerebral Palsy

NCT06530680
View directory record Official record
Conditions
Autism Spectrum Disorder, Cerebral Palsy
Interventions
Hippotherapy
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
6 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 10, 2026, 9:41 AM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), Placebo, LOU064 (open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
43
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 10, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

NCT02651428
View directory record Official record
Conditions
Kidney Failure, Chronic, Catheter-Related Infections
Interventions
Neutrolin, Heparin
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 10, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01155375
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Oral Iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 10, 2026, 9:41 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
Interventions
ABBV-319
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 10, 2026, 9:41 AM EDT